Showing 1501-1510 of 1735 results for "".
- Haag-Streit Announces Winners of its Slit Lamp Imaging Competition 2023https://modernod.com/news/haag-streit-announces-winners-of-its-slit-lamp-imaging-competition-2023/2481881/Attracting over 350 images from around the world, Haag-Streit Announced its top three winners of its Slit Lamp Imaging Competition 2023. The winners were judged on on image quality, technical execution, and disease interest. • First place: Pia Emilia Lohr
- Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trialhttps://modernod.com/news/nicox-announces-last-patient-completed-ncx-4251-mississippi-phase-2b-blepharitis-trial-2/2479337/Nicox SA announced that the last patient in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial has now completed the two-week treatment phase, as well as the required two-week, follow-up period. Top-line results are expected to be announced in September 2021. “The Phase 2b Missis
- Ceyeber Announces Advisory Board of World-Renowned Ophthalmologistshttps://modernod.com/news/ceyeber-announces-advisory-board-of-world-renowned-ophthalmologists/2479167/Ceyeber, the developer of implantable intraocular lens technology designed for medical applications and augmented reality, has created a Medical Advisory Board consisting of top ophthalmologists. Ceyeber’s founder and CEO, Robert E. Grant, said, “
- Novaliq Announces More Than Half of Patients Enrolled in CyclASol Phase 3 Dry Eye Disease Trial ESSENCE-2https://modernod.com/news/novaliq-announces-more-than-half-of-patients-enrolled-in-cyclasol-phase-3-dry-eye-disease-trial-essence-2/2479125/Novaliq announced today that the second Phase 3 clinical trial evaluating CyclASol to treat the signs and symptoms of dry eye disease (DED) has randomized more than 50% out of 834 targeted patients, with top-line results expected in the second half of 2021. The Phase 3 program for CyclASol
- Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Material Recycled Through One By One Recycling Programhttps://modernod.com/news/bausch-lomb-reports-nearly-27-million-united-of-contact-lens-material-recycled-through-one-by-one-recycling-program/2478541/Bausch + Lomb announced that its exclusive ONE by ONE Recycling program has recycled nearly 27 million used contact lenses, top foils and blister packs since launching in November 2016. The program, made possible through a collaboration with TerraCycle, a leader in the collection and repurposing
- Vision Expo Introduces InFocus Video Serieshttps://modernod.com/news/vision-expo-introduces-infocus-video-series/2478114/Vision Expo announced the launch of InFocus, a series of 4-minute video interviews with some of Vision Expo’s top industry attendees and OPTImum program buyers conducted by Suzanne Krauss, OPTImum Program Manager at Vision Expo. The InFocus Series launches this week with a new video to be
- Novavax Granted Up to $384 Million in New CEPI Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-granted-up-to-384-million-in-new-cepi-funding-for-covid-19-vaccine-candidate/2477747/Novavax announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in March, to advance clinical development of the company’s vaccine candidate NVX-CoV2373 against SARS-CoV-2. In Ap
- NovaBay Pharmaceuticals to Distribute the NuLids System for the Treatment of Dry Eye in Certain U.S. Geographieshttps://modernod.com/news/novabay-pharmaceuticals-to-distribute-the-nulids-system-for-the-treatment-of-dry-eye-in-certain-u-s-geographies/2477048/NovaBay Pharmaceuticals announced an exclusive 90-day agreement with NuSight Medical to distribute the NuLids System for treatment of blepharitis and dry eye in six of NovaBay’s top-performing territories. The NuLids System is a hand-held, cordless device that safely and effectively removes accum
- Ex-Shire CEO Flemming Ornskov Emerges as Galderma CEO after $10B Nestlé Spinouthttps://modernod.com/news/ex-shire-ceo-flemming-ornskov-emerges-as-galderma-ceo-after-10b-nestle-spinout/2476966/As Takeda folds in Shire, two of the Irish rare disease specialist’s former top leaders have found themselves a new home at Nestlé skin health spinoff Galderma, according to a report in FiercePharma. Flemming Ornskov, Shire’s most recent CEO before the Takeda buyout, has
- Market Scope: Advancing Technology Drives Ophthalmic OR Microscope Market to 6 Percent Growth by 2024https://modernod.com/news/market-scope-advancing-technology-drives-ophthalmic-or-microscope/2476746/Manufacturers continue to push the envelope integrating advanced technology into the surgical suite with their top-of-the-line ophthalmic OR microscopes, bringing 4K and 3-D heads-up display with integrated diagnostics—for those who can afford the price tag. Market Scope expects the global